Renée J. Goldberg Arnold completed her undergraduate training at the University of Maryland and received her Doctor of Pharmacy degree from the University of Southern California in Los Angeles. She also completed a one-year post-doctoral residency at University Hospital in San Diego, which is affiliated with the University of California at San Francisco School of Pharmacy. Dr. Arnold was previously President and Co-Founder of Pharmacon International, Inc. Center for Health Outcomes Excellence; Senior Vice President, Medical Director, William J. Bologna International, Inc., a pharmaceutical marketing and advertising agency; and Assistant Professor of Clinical Pharmacy at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University (LIU) in Brooklyn, NY. Her research interests at that time were plasma amino acid concentrations in very low birth weight infants and home-infusion total parenteral nutrition.
Dr. Arnold is currently President and CEO, Arnold Consultancy & Technology LLC, with headquarter offices in New York City, where she develops and oversees outcomes research and affiliated software for the pharmaceutical, biotech and device industry and federal government programs. Her special interest in evidence-based health derives from her research that deals with use of technology to collect and/or model real-world data for use in rational decision-making by healthcare practitioners and policy makers. Dr. Arnold’s academic titles include Adjunct Associate Professor, Master of Public Health program, Department of Community and Preventive Medicine at the Mount Sinai School of Medicine, where she has developed the pharmacoeconomics coursework and is a preceptor for MD/MPH students completing their MPH practicums. She is also Full Adjunct Professor, Div. of Social Sciences and Administrative Sciences, at LIU. In that capacity, she serves as a preceptor for undergraduate and graduate students completing rotations in health outcomes and pharmacoeconomics research. Dr. Arnold also initiated internship and post-doctoral fellowship programs in pharmacoeconomics at Arnold Consultancy & Technology LLC and is a founding member and former Chair of the Education Committee of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), as well as current Chair of the Health/ Disease Management Special Interest Group. In addition, she is a licensed pharmacist. Dr. Arnold is the author of numerous articles in the areas of pharmacology, pharmacoeconomics and cost containment strategies and is a co-author of five book chapters, one in cardiovascular therapeutics, another in pharmacoeconomic analyses in cardiovascular disease, the third in computer applications in pharmaceutical research and development, the fourth in quality of life and cost of atopic dermatitis and the fifth in the reliability and validity of claims and medication databases as data sources for health/disease management programs and author and editor of a forthcoming book, entitled, Introduction to Pharmacoeconomics: From Theory to Practice (CRC Press, 2009). Dr. Arnold is married with a sixteen-year-old son who keeps her busy.
Mr. Arnold is the Director of FACITtrans. He and his team have been responsible for coordinating and managing the translation and linguistic validation of over 50 FACIT questionnaires into over 60 languages and delivering high quality translations of other Patient Reported Outcomes (PRO) measures used in multilingual clinical trials. This group is also conducting Spanish translations for NeuroQol, PROMIS and Toolbox, three major federal projects. Mr. Arnold is a member of the American Translators Association (ATA), the International Society for Quality of Life Research (ISOQOL) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He has conducted workshops in multiple languages on translation and cross-cultural issues at conferences worldwide and is FACIT's Latin American presence residing in Fortaleza, Brazil. Mr. Arnold holds an MA in Multicultural and Corporate Communication from DePaul University, Chicago and a BA in Spanish (Linguistics) with a minor in Portuguese from the University of Arizona.
Onur Baser, MS, PhD, is Adjunct Professor of Internal Medicine at The University of Michigan and President & CEO of STATinMED Research.
Dr. Baser's work in the field of propensity score matching was one of the first applications of econometric techniques in outcomes research to provide guidelines for choosing among different types of matching techniques.
He created ProbChoice™ , SIFRA™, CompScore™, NatWeight™, SES™, and SAMPSIZE™ algorithms. His co-authored work created a composite score, which is used by the National Institute of Health to profile U.S. hospitals. He adopted a weight mechanism to create national representative data sets using private insurance databases. His ZIP code-linked socioeconomic status variable is frequently used in outcomes research studies and can link any data set.
He is a frequent speaker at national and international conferences. In the last 3 years, he taught the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) pre-conference short courses regarding "Modeling using Real-world Data". He has been selected as a professor for the distance learning program by the same society.
Dr. Baser's webinars on estimating health care cost models, comparison of propensity score matching techniques, and selection bias issues in outcomes research attract researchers from a wide variety of disciplines and institutions. He also serves as a litigation expert on statistical issues.
Dr. Baser has over 250 worldwide presentations and publications, and contributed to several book chapters. His book on estimation of health care costs will be published in April. His publication on propensity score matching was selected as one of the Top 10 most read Value in Health articles, and his co-authored work on quality measurement appeared in JAMA in 2009, and was cited in several radio shows and newspapers.
Jill A. Bell, PhD, supports the development and execution of strategies to incorporate valid clinical outcome assessment (COA) measures into clinical trials to create differentiated product profiles, provide meaningful information to physicians, patients, and payers, and when appropriate, include COA claims and their use in medical product development to support labeling. Dr. Bell has spent the last several years working in both industry and the consulting area, performing outcomes research studies. She has extensive experience in the development and validation of COA measures and also worked to establish recommendations for the measurement and reporting of health-related quality of life to support labeling and promotional claims.
Bijan J. Borah, PhD, is an Associate Professor of Health Services Research at Mayo Clinic College of Medicine, Rochester, Minnesota, USA. His primary research interest is in the area of comparative effectiveness research (CER), with specific focus on methodological issues in CER. His CER research projects cut across different disease areas including diabetes, cardiovascular diseases, and uterine fibroids. In the CER methods arena, Dr. Borah has been involved in multiple projects in propensity score methods as well as methods for assessing medications adherence. Dr. Borah's was the principal investigator of a study funded by Focused Ultrasound Foundation that assessed comparative effectiveness of different treatment procedures for the treatment of uterine fibroids. Dr. Borah is also the co-investigator of two other CER studies in uterine fibroids, one of which has been funded by National Institutes of Health while the other has been funded jointly by Agency for Healthcare Research and Quality, and Patient-Centered Outcomes Research Institute.
Dr. Borah received his bachelors and masters in Statistics from Delhi University, India. He obtained an MPhil in Development Studies from Indira Gandhi Institute of Development Research, Mumbai, India. Subsequently, Dr. Borah graduated with a PhD in Economics from Indiana University Bloomington. Prior to joining Mayo Clinic in 2010, Dr. Borah was a Senior Researcher and Associate Director at OptumInsight (formerly i3 Innovus), a UnitedHealth company. At Mayo Clinic Medical School, besides his research activities, Dr. Borah also teaches courses on economic evaluation and propensity score methods.
Dr. Brogan is the Head of Decision Analytic Modeling in US Health Economics at RTI Health Solutions. She has a PhD in Operations Research with a special emphasis on financial portfolio optimization. She has been with RTI Health Solutions for over 10 years during which time she has developed cost-effectiveness, budget-impact, and population models; cost-consequence analyses; and product value dossiers. She has experience with a variety of modeling procedures, including Markov and other stochastic models, simulation, regression, linear and nonlinear programming, and various types of sensitivity analysis. Dr. Brogan has developed models and analyses in the areas of HIV, hepatitis C, influenza, diabetic nephropathy, oncology, osteoporosis, chronic pain, age-related macular degeneration, schizophrenia, bipolar disorder, epilepsy, bone healing, hospital-acquired infection, and vehicle routing. Her research has been presented at various professional conferences and published in several peer-reviewed journals, including AIDS, American Journal of Health-System Pharmacy, American Journal of Preventative Medicine, European Journal of Operational Research, HIV Clinical Trials, Pharmacoeconomics, and Value in Health.
Dr. Karon F. Cook is Research Associate Professor in the Department of Medical Social Sciences at Northwestern University Feinberg School of Medicine, Chicago. She is a psychometrician and health outcomes researcher with particular interest in applied psychometric research and in developing effective ways to communicate the science of measurement in cogent and accessible ways. Her research expertise includes item response theory, computer adaptive scaling, evaluation of differential item function, and pain assessment.
The bulk of Dr. Cook's applied work has been in the development and evaluation of self-report measures. She has developed measures for a diverse range of patient outcomes including shoulder function, pain intensity and pain behaviors. Dr. Cook has been principle investigator for research funded by National Institutes of Health, Agency for Healthcare Research and Quality (AHRQ), Veteran's Affairs Health Services Research, Veteran's Affairs Rehabilitation Research, and the Department of Defense.
Helena Correia is Translation Manager and Research Project Manager in the Department of Medical Social Sciences, Feinberg School of Medicine, at Northwestern University. Ms. Correia earned a Licenciatura in International Relations from Universidade do Minho, Portugal, and has been involved in PRO translation for over ten years. She has conducted presentations and facilitated workshops on PRO translation methodology at conferences in both Europe and North America and has served as senior advisor on translation and cross-cultural adaptation matters, namely for the NIH-funded PROMIS, Neuro-QOL and Toolbox projects. In that capacity she reviews research protocols, conducts translatability assessments and serves as liaison to researchers around the world who are interested in translating and using these measures. Ms. Correia's more direct involvement in the translation process consists of guiding project coordinators and researchers through the resolution of translation issues, and overseeing the quality and harmonization of the translations. She has developed and continues to promote standards and guidelines for translatability assessment and translation of instruments that are suitable for culturally diverse populations while conceptually and linguistically equivalent to the source.
Dr. Earnshaw is the Vice President of Health Economics at RTI Health Solutions. She has a PhD in Industrial Engineering with a special emphasis on optimization, resource allocation, and stochastic processes. Dr. Earnshaw has been with RTI Health Solutions for over 14 years during which time she has developed innovative mathematical models to determine pricing strategy, budget impact, and cost-effectiveness of new health care technologies. She has experience using a variety of mathematical techniques, including Markov models, Monte Carlo and discrete event simulation models, mathematical programming models (e.g., linear and integer programming), machine scheduling, network optimization, stochastic modeling, and personnel-assignment models. She has developed models and performed analyses for pharmaceuticals and diagnostics/medical devices and in the areas of cardiovascular disease, gastrointestinal disease, respiratory disease, neurology, transplant, infectious disease, oncology, and men's health. She has presented her work at professional conferences and has published in a variety of peer-reviewed journals, including Annuals of Internal Medicine, Archives of Internal Medicine, Medical Decision Making, Value in Health, Journal of American Society of Nephrology, Stroke, and Pharmacoeconomics.
Dr. Ganz is Director of Health Services Research at Abt Bio-Pharma Solutions, Inc. Dr. Ganz' skills and experience are in health economics, program evaluation, and the analysis and management of health-related survey data. Prior to joining Abt Associates/Abt Bio-Pharma Solutions, Dr. Ganz was an Assistant Professor at the Harvard School of Public Health in the Department of Society, Human Development, and Health where he developed and continues to teach, as an Adjunct Assistant Professor, courses on the analysis of secondary data. Dr. Ganz has conducted publicly- and privately-funded research on health behavior decision-making, health care utilization and expenditures of special populations, including children with special health care need and has worked extensively with large representative national health surveys such as the Medical Expenditure Panel Survey and the National Health Interview Survey, as well as with health insurance claims. He has published on the epidemiology and utilization and expenditure patterns of a number of health conditions and special populations in leading journals such as the American Journal of Public Health, Health Economics, Ophthalmology, Pediatrics, and the Archives of Pediatrics and Adolescent Medicine.
Dr. Ganz has a number of research interests including investigating the correlates and predictors of health care utilization and expenditures among subjects with specific disease conditions and among special populations such as children; policy analysis and economic evaluations of the indirect effects of non-health policies on health; investigation health status and health behaviors using health economics models and econometric methods. Dr. Ganz has a PhD in Sociomedical Sciences and an MS in Biostatistics, both from Columbia University in New York, and a BS in Economics from UCLA. Dr. Ganz is an active referee for a number of economic and clinical journals and is a member of a number of public health and health economics associations.
Dr. Jan Hirsch is Assistant Professor of Clinical Pharmacy in the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. She received her B.S. in Pharmacy and M.S. and Ph.D. degrees in Pharmacy Administration from the University of South Carolina, College of Pharmacy. She is responsible for coursework in Health Policy and Pharmacoeconomics and received an Excellence in Teaching Award in May 2004.
Prior to joining the UCSD faculty, she spent 14 years in the pharmaceutical and managed care industry where she was responsible for establishing and managing outcomes research departments for two pharmaceutical companies (Glaxo Group Research in Greenford (UK) and Allergan (US)) and a pharmacy benefit management company (Prescription Solutions (US)).
Dr. Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically,
1) Assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals in clinical trials or observational studies across therapeutic areas.
2) Integrating patient reported outcomes (PRO's) (e.g. burden elements, Quality of Life, satisfaction) into pharmaceutical and medical care practices to improve patient management – with emphasis on:
- developing and validating PRO instruments
- assessing outcomes status in patient populations
- identifying patients who will likely benefit most – realize greatest value – from interventions
Key current therapeutic areas of interest: diabetes, gout, HIV/AIDS, and mental health
David A. Holdford, BSPharm., MS, PhD, FAPhA, is Associate Professor of Pharmacy at Virginia Commonwealth University (VCU) at the Medical College of Virginia in Richmond. At VCU, Dr. Holdford conducts research, teaches professional and graduate students, and consults in the areas of pharmaceutical marketing, health outcomes research, and medication safety. Dr. Holdford is the author of the book Marketing for Pharmacists from APhA Publications, and co-editor of the book Leadership and Advocacy for Pharmacy. His new text, Introduction to Institutional Pharmacy Practice, will be published in 2010. He has authored over 60 papers and book chapters in health care and business publications. Prior to joining the faculty at Virginia Commonwealth University in 1995, Dr. Holdford completed his BS in Pharmacy at University of Illinois in Chicago, MS in Pharmacy Administration at Ohio State, and PhD in Pharmacy Administration at the University of South Carolina. He has worked as a pharmacist and manager at hospitals in Chicago, Illinois and Columbia, South Carolina.
Dr. Holdford has been an ISPOR member since its beginning. He is particularly interested in bridging the gap between pharmacoeconomics theory and its application to problems in medication use.
Dr. Tamar Lasky earned her PhD in Epidemiology at the University of North Carolina at Chapel Hill School of Public Health. Her research interests include pediatric pharmacoepidemiology, medication information, vaccine safety, food safety and systematic literature review and meta-analysis. She is President and owner of MIE Resources, a company that provides expertise in analysis and synthesis of information about public health, medication use and safety. She has 25 years of experience in government and academia including faculty positions at the University of Maryland, Baltimore School of Medicine and the University of Rhode Island College of Pharmacy. As staff scientist at the National Institute of Child Health and Human Development (NICHD) she provided epidemiologic expertise for implementation of Best Pharmaceuticals for Children Act (BPCA). Her most recent book is What Pharmacists Need to Know About Racial and Ethnic Health Disparities. She edited the book, Epidemiologic Principles and Food Safety, co-authored two other books, and has authored numerous peer-reviewed research publications. Dr. Lasky is a member of ISPOR, and ISPE. She is the founding Chair of the ISPE Pediatrics Special Interest Group, and is a reviewer for JAMA, Pediatrics, and Pharmacoepidemiology and Drug Safety and other scientific journals.
Susan D. Ross, MD, FRCPC, is an independent consultant in Evidence-based Medicine, providing her unique expertise to clients engaged in the development and delivery of healthcare services and products. Dr. Ross was previously a co-founder of MetaWorks, an AHRQ Evidence-based Practice Center specializing in systematic reviews and meta-analyses. As Chief Science Officer, she led MetaWorks’ technical teams for 10 years in providing clinical and analytic consulting services to pharma and biotech industry clients, in addition to government contract work. She has over 60 publications to date. In 2006, MetaWorks was acquired by United BioSource Corporation, a global pharmaceutical services company, where Dr. Ross continued for a transition year as a Vice President of Medical Affairs.
Prior to MetaWorks, Dr. Ross was Vice President of Clinical Research at a Boston-based biotech company during its rapid growth and transition from a venture-funded research group through a successful IPO. Dr. Ross is a graduate of the advanced course in Biomedical Research Management at the Harvard School of Public Health, and an honors graduate of the University of Toronto Faculty of Medicine. She is board-certified in Internal Medicine in both Canada and the U.S., where she continues a part-time clinical practice in a Boston area clinic.
Elizabeth Unni is currently an Assistant Professor with the Department of Pharmaceutical Sciences at the Roseman University of Health Sciences College of Pharmacy. She also holds an adjunct faculty position with the Department of Pharmacotherapy at the University of Utah. Dr. Unni received her Bachelor of Pharmacy degree from the College of Pharmaceutical Sciences, Manipal, India. She came to the United States in 2001 to pursue a Masters degree in Business Administration at the University of Louisiana at Monroe. Subsequently, she joined the University of Iowa for her PhD in Pharmaceutical Socioeconomics and graduated in 2008. Dr. Unni has publications in peer reviewed journals and has also presented her research at various regional and national conferences. She has also received various awards for her research at both college and regional levels. Elizabeth's research interest is in patient-reported outcomes and include medication non-adherence, medication errors, medication management by elderly, and medication therapy management services. She is a member of the American Pharmaceutical Association, the American Association of Colleges of Pharmacy, International Society for Pharmacoeconomics and Outcomes Research, International Society of Quality of Life, Beta Gamma Sigma, and Rho Chi Academic Honor Societies.
Dr Jennifer Whitty is Deputy Director of the Population and Social Health Research Program, Griffith Health Institute and a Senior Lecturer with the Centre for Applied Health Economics at the School of Medicine, Griffith University. She has substantial research leadership and consultancy experience in health economics and health services research, including in evaluating preferences and quality of life, economic evaluation, and health technology assessment. Jennifer leads a program of research centred on eliciting public and decision-maker preferences and choices around health care, and using these preferences to inform economic evaluation and health care decision making. Her research is also developing methodologies for measuring preferences and valuing quality of life, and she is an expert in the application of choice-based stated preference methods such as the discrete choice experiment. Jennifer leads a number of projects applying stated preference methods in health. In 2010, she was awarded a prestigious Smart Futures Fellowship by the Queensland Government to support her research. Jennifer has published in numerous peer-reviewed journals and is a member of the Editorial Board for the international journal "Applied Health Economics and Health Policy". Jennifer's first qualification is as a pharmacist, and prior to developing her research expertise she has diverse experience in pharmacy practice, including positions in hospital, community, academic, and policy settings, in the UK and Australia. Jennifer's research has retained a particular focus on the evaluation of health technologies including pharmaceuticals and related health policy.